43 related articles for article (PubMed ID: 10218511)
1. Targeting microenvironment in cancer therapeutics.
Martin M; Wei H; Lu T
Oncotarget; 2016 Aug; 7(32):52575-52583. PubMed ID: 27270649
[TBL] [Abstract][Full Text] [Related]
2. The Role of Nephrectomy for Kidney Cancer in the Era of Targeted and Immune Therapies.
Vaishampayan UN
Am Soc Clin Oncol Educ Book; 2016; 35():e16-20. PubMed ID: 27249719
[TBL] [Abstract][Full Text] [Related]
3. Cutting Edge: Engineering Active IKKβ in T Cells Drives Tumor Rejection.
Evaristo C; Spranger S; Barnes SE; Miller ML; Molinero LL; Locke FL; Gajewski TF; Alegre ML
J Immunol; 2016 Apr; 196(7):2933-8. PubMed ID: 26903482
[TBL] [Abstract][Full Text] [Related]
4. Tumor gangliosides accelerate murine tumor angiogenesis.
Liu Y; Wondimu A; Yan S; Bobb D; Ladisch S
Angiogenesis; 2014 Jul; 17(3):563-71. PubMed ID: 24165965
[TBL] [Abstract][Full Text] [Related]
5. Cancer prevention with promising natural products: mechanisms of action and molecular targets.
Pratheeshkumar P; Sreekala C; Zhang Z; Budhraja A; Ding S; Son YO; Wang X; Hitron A; Hyun-Jung K; Wang L; Lee JC; Shi X
Anticancer Agents Med Chem; 2012 Dec; 12(10):1159-84. PubMed ID: 22583402
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapy in renal cancer.
Dorff TB; Goldkorn A; Quinn DI
Ther Adv Med Oncol; 2009 Nov; 1(3):183-205. PubMed ID: 21789121
[TBL] [Abstract][Full Text] [Related]
7. Immune responses to malignancies.
Whiteside TL
J Allergy Clin Immunol; 2010 Feb; 125(2 Suppl 2):S272-83. PubMed ID: 20061007
[TBL] [Abstract][Full Text] [Related]
8. The tumor microenvironment and its role in promoting tumor growth.
Whiteside TL
Oncogene; 2008 Oct; 27(45):5904-12. PubMed ID: 18836471
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of CD4+ T cell activities and modulation of Th1/Th2 lineage development in radiated tumor-bearing rats treated with male zooid of Antheraea pernyi extracts.
Zhao WH; Li L; Zhang B; Zhang WD; Zong M; Tang JD; Zhang HY; Li S
World J Gastroenterol; 2008 Apr; 14(13):2094-9. PubMed ID: 18395913
[TBL] [Abstract][Full Text] [Related]
10. Signaling defects in anti-tumor T cells.
Frey AB; Monu N
Immunol Rev; 2008 Apr; 222():192-205. PubMed ID: 18364003
[TBL] [Abstract][Full Text] [Related]
11. Adoptive immunotherapy of cancer with polyclonal, 108-fold hyperexpanded, CD4+ and CD8+ T cells.
Wang LX; Huang WX; Graor H; Cohen PA; Kim JA; Shu S; Plautz GE
J Transl Med; 2004 Nov; 2(1):41. PubMed ID: 15566571
[TBL] [Abstract][Full Text] [Related]
12. Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape?
Malmberg KJ
Cancer Immunol Immunother; 2004 Oct; 53(10):879-92. PubMed ID: 15338206
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of zeta-chain expression in T cells: a biomarker of prognosis in cancer?
Whiteside TL
Cancer Immunol Immunother; 2004 Oct; 53(10):865-78. PubMed ID: 15118842
[TBL] [Abstract][Full Text] [Related]
14. Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress.
Mantovani G; Macciò A; Madeddu C; Mura L; Gramignano G; Lusso MR; Massa E; Mocci M; Serpe R
J Mol Med (Berl); 2003 Oct; 81(10):664-73. PubMed ID: 12928788
[TBL] [Abstract][Full Text] [Related]
15. Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappaB activation in T cells.
Uzzo RG; Rayman P; Kolenko V; Clark PE; Cathcart MK; Bloom T; Novick AC; Bukowski RM; Hamilton T; Finke JH
J Clin Invest; 1999 Sep; 104(6):769-76. PubMed ID: 10491412
[TBL] [Abstract][Full Text] [Related]
16. Alterations in NFkappaB activation in T lymphocytes of patients with renal cell carcinoma.
Uzzo RG; Clark PE; Rayman P; Bloom T; Rybicki L; Novick AC; Bukowski RM; Finke JH
J Natl Cancer Inst; 1999 Apr; 91(8):718-21. PubMed ID: 10218511
[No Abstract] [Full Text] [Related]
17. Mechanisms of immune evasion by renal cell carcinoma: tumor-induced T-lymphocyte apoptosis and NFkappaB suppression.
Ng CS; Novick AC; Tannenbaum CS; Bukowski RM; Finke JH
Urology; 2002 Jan; 59(1):9-14. PubMed ID: 11796271
[No Abstract] [Full Text] [Related]
18. Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: clinical relevance and effects of cytokine therapy.
Bukowski RM; Rayman P; Uzzo R; Bloom T; Sandstrom K; Peereboom D; Olencki T; Budd GT; McLain D; Elson P; Novick A; Finke JH
Clin Cancer Res; 1998 Oct; 4(10):2337-47. PubMed ID: 9796963
[TBL] [Abstract][Full Text] [Related]
19. Tumor-induced dysfunction in interleukin-2 production and interleukin-2 receptor signaling: a mechanism of immune escape.
Rayman P; Uzzo RG; Kolenko V; Bloom T; Cathcart MK; Molto L; Novick AC; Bukowski RM; Hamilton T; Finke JH
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S81-7. PubMed ID: 10685665
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
